| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 7.2 | 13.8 |
| Net income | -127.5 | -101.3 |
| EPS (diluted, $ a share) | $-0.91 | $-0.92 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -48.0% |
|---|
10-Q filed with the SEC, NASDAQ: NTLA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Intellia Therapeutics, Inc.: key numbers
- Share price
- $9.86Close, Nov 16
- Market cap
- $1.38B
- Shares outstanding
- 140.36MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Intellia Therapeutics, Inc.
All →Intellia Therapeutics Investor Presentation
Intellia Therapeutics hosted a webcast and filed a formal investor presentation titled 'Readying Lonvo-z for Patients with HAE.' The presentation focused on the commercial potential and clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema.
Intellia Therapeutics Investor Presentation
Intellia Therapeutics hosted a webcast for investors and analysts titled 'Readying Lonvo-z for Patients with HAE' to discuss the development and commercialization strategy for its CRISPR-based therapy, lonvoguran ziclumeran. The presentation focused on the clinical data and market potential for lonvo-z in treating hereditary angioedema (HAE).
Intellia Therapeutics Financial Results
Intellia Therapeutics reported Q3 2026 financial results, highlighting the FDA's acceptance and Priority Review of the BLA for lonvo-z with a PDUFA date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and expects its current cash position to fund operations into 2028.
- Counterparty
- Regeneron Pharmaceuticals, Inc.
- Term
- Q3 2026
“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead. We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”
John Leonard, M.D., Intellia President and Chief Executive Officer
Intellia Therapeutics President and CEO John M. Leonard Sells $108K of Stock
John M. Leonard, President and CEO, sold 9,000 shares of Intellia Therapeutics, Inc. at $11.99 a share, worth $108K in total on Nov 2, 2026. Shares held after the trade: 1,138,064 (-0.8%).
- Value
- $108K
- Shares
- 9,000
- Price
- $11.99
- Role
- President and CEO
- Holding change
- -0.8%
- Trade date
- Nov 2, 2026
Intellia Therapeutics VP, CAO Michael P. Dube Sells $23.2K of Stock
Michael P. Dube, VP, CAO, sold 1,864 shares of Intellia Therapeutics, Inc. at $12.43 a share, worth $23.2K in total on Oct 2, 2026. Shares held after the trade: 65,022 (-2.8%).
- Value
- $23.2K
- Shares
- 1,864
- Price
- $12.43
- Role
- VP, CAO
- Holding change
- -2.8%
- Trade date
- Oct 2, 2026